To examine the mechanism of dual blockade of CDK4/6 and MEK on KRAS mutant CRC cells, cell growth was assessed with MTS assay after treatment with MEK162 and palbociclib for 72 hours. The gene discussed is KRAS; the disease is colorectal carcinoma.